Metabolon announces publication of metabolic analysis of biochemical changes in CF primary lung epithelial cells

NewsGuard 100/100 Score

Metabolon, Inc., the leader in global metabolomics, biomarker discovery and analysis, announces the publication of "Metabolomic Profiling Reveals Biochemical Pathways and Biomarkers Associated with Pathogenesis in Cystic Fibrosis Cells", in the Journal of Biological Chemistry (2010, Vol. 285, No. 40, Pages 30516-30522). The article describes the application of non-targeted biochemical profiling (metabolomics) to study the biochemical changes in human lung epithelial cell lines of cystic fibrosis (CF) patients. The study was carried out in collaboration with the Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), a nonprofit subsidiary of the Cystic Fibrosis Foundation, and CF researchers from the University of Pittsburgh funded by CFFT.

“Metabolomic Profiling Reveals Biochemical Pathways and Biomarkers Associated with Pathogenesis in Cystic Fibrosis Cells”

The identification of the cystic fibrosis transmembrane conductance regulator (CFTR) gene has lead to many genetic and molecular biology studies which have aided our understanding of the effects of gene mutations on the CFTR protein. Yet, how the CFTR defects lead to downstream biological changes and the resulting CF clinical symptoms remains unclear. In the JBC report, the investigators used metabolomics to gain an initial understanding of the global biochemical alterations in CF primary lung epithelial cells. The authors measured changes in glucose, sorbitol and pentose phosphate metabolism that could serve to exacerbate CF-associated oxidative stress as well as other metabolic changes that suggest altered purinergic signaling.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New MOBE technology revolutionizes multiplexed genome editing